Drug Profile
Tedizolid - Merck & Co
Alternative Names: BAY 1192631; DA-70157; DA-70218; DA-7157; DA-7218; MK-1986; SIVEXTRO; Sivextro; Tedizolid phosphate; Torezolid; Torezolid phosphate; TR-700; TR-701; TR-701 FA; TR-701 free acidLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Dong-A Pharmaceutical
- Developer Dong-A ST; Merck & Co
- Class Anti-infectives; Antibacterials; Fluorinated hydrocarbons; Oxazolidinones; Phosphates; Pyridines; Small molecules; Sodium compounds; Tetrazoles
- Mechanism of Action Ribosomal protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Skin and soft tissue infections
- Phase III Nosocomial pneumonia; Ventilator associated pneumonia
- No development reported Bacteraemia; Gram-positive infections
Most Recent Events
- 06 Jul 2023 Merck & Co completes a phase-III trial in Skin and soft tissue infections (In children, In infants) in US, Georgia, Guatemala, Latvia, Lithuania, Russia, Ukraine, Turkey, South Africa, Poland, Mexico, Germany, Bulgaria and Brazil (IV) (NCT03176134)
- 26 Aug 2022 No development reported - Phase-I for Ventilator-associated-pneumonia in USA (PO)
- 05 May 2022 Nabriva extends agreement with Merck to promote and distribute tedizolid in USA till December 2026